IL6 and rheumatoid arthritis: In addition, treatment targeted at macrophages, such as IL-6 and TNF-α inhibition, and at B-lymphocytes and not to T-lymphocytes, showed better efficacy in murine models and joined case reports of RA patients with scleritis [151].